Lung Cancer Support Nurse - Lung Foundation Australia Quit Centre | Homepage Lung Cancer Screening Program: Early Detection Saves Lives (thoraciconcology.org.au) Lung Cancer Optimal Care Pathway ..read more

Artificial intelligence (AI) is transforming medicine. Lung Cancer healthcare professionals are interested in the use of AI in radiology, particularly in early diagnosis leading to better patient outcomes. In this podcast we will explore how AI can aid in early detection, accurate interpretation of imaging scans and reduce diagnostic errors. This episode is joined by Associate Professor Michael Franco, a dual trained in medical oncology and palliative care and also the digital health director at Monash in Melbourne. He is featured with Professor Catherine Jones Cardiothoracic Radiologist I-Med ..read more

In this TOGA Podcast the speakers discuss Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer. The discussion explores the different molecules and mechanisms of drugs currently available, trial results and the subsequent place of ADCs in the Lung Cancer. Furthermore, our guests expand upon the management of patients receiving these drugs. A/Prof Melissa Moore, Medical Oncologist at St Vincent’s Hospital Melbourne, is joined in this conversation by fellow medical oncologists A/Prof Tom John from Peter MacCallum Cancer Centre in Melbourne and A/Prof Adnan Nagrial from ..read more

This TOGA Podcast discusses strategies for enhancing patients’ recovery from lung cancer resection in light of new and emerging data for new peri-operative therapies that improve survival. The conversation explores the guidelines available, the changing landscape for the patient with neoadjuvant and adjuvant management options, and the multidisciplinary considerations to optimise the care of patients. Dr Jazmin Eckhaus, a thoracic surgeon from The Austin, Melbourne, is joined by A/Prof Emily Stone, Head of Thoracic Medicine in the Dept of Thoracic Medicine and Lung Transplantation at St Vincen ..read more

This TOGA Podcast discusses the data surrounding air pollution and lung cancer. The discussion delves into Nature and nurture and lung cancer risk and implications for future screening. Associate Professor Tom John, Medical Oncologist from Peter MacCallum Cancer Centre, is joined by Professor Charles Swanton, The Group Leader at the Cancer Therapeutics Laboratory at the London Research Institute and Medical Oncologist from University College in London, Associate Professor Venessa Chin, a Medical Oncologist from St Vincent’s Private Hospital, Kinghorn Cancer Centre and Garvan Institute and Dr T ..read more

In this TOGA Podcast, we discuss what defines operability in locally advanced stage III NSCLC. A/Professor Tim Clay, Medical Oncologist from St John of God Subiaco and Rockingham General is joined by Professor Lucy Morgan, Board Chair of the Lung Foundation of Australia and Respiratory Physician from Concord & Nepean Hospitals; A/Professor Phillip Antippa, Cardiothoracic surgeon and the Head of Thoracic Surgical Services at the Royal Melbourne Hospital and the VCCC and also Dr Qurrat van den Blink, Radiation Oncologist from GenesisCare based in Perth (Joondalup) and Albany ..read more

In this TOGA Podcast, we discuss what defines operability in locally advanced stage III lung cancer. A/Professor Tim Clay, Medical Oncologist from St John of God Subiaco and Rockingham General is joined by Professor Lucy Morgan, Board Chair of the Lung Foundation of Australia and Respiratory Physician from Concord & Nepean Hospitals; A/Professor Phillip Antippa, Cardiothoracic surgeon and the Head of Thoracic Surgical Services at the Royal Melbourne Hospital and the VCCC and also Dr Qurrat van den Blink, Radiation Oncologist from GenesisCare based in Perth (Joondalup) and Albany ..read more

For lung cancer patients, the benefits of treatment and potential for cure must always be balanced with risk. Cardiotoxicity is considered a short and long term risk from treatment for lung cancer, but this varies between patients. New radiotherapy techniques, lower doses of radiotherapy and supporting cardiovascular treatments can minimise the risk of cardiotoxicity. Monitoring for cardiac complications is becoming an important aspect of survivorship care, and may require collaboration between medical oncologists, radiation oncologists, GPs and cardiologists.  Professor Shalini Vinod, Th ..read more

Deme Karikios, Medical Oncologist and Director of Clinical trials at Nepean Cancer Care Centre in Sydney is joined by Wanda Cui, Medical Oncologist from the Peter MacCallum Cancer Centre in Melbourne and Chris Karapetis,  Head of the Department of Medical Oncology and Director of Clinical Research at the Flinders Medical Centre in Adelaide ..read more

The identification of molecular subtypes of non-squamous NSCLC continues to grow, spurring the development of targeted therapies designed to target these mutations and prevent the growth of the cancer. People with advanced NSCLC that possess one of these ‘actionable’ mutations and can access targeted treatments can live for many years with very manageable side effects. However, the technology to identify these actionable mutations in a single test and the targeted treatments are not yet accessible to all people with advanced NSCLC. In this TOGA podcast, we explore access to molecular diagnosti ..read more